> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Novartis sNDA for Entresto
- URL: https://www.fdaweb.com/panel-to-discuss-novartis-snda-for-entresto/
- Published: 2020-10-27T12:00:00.000Z
- Updated: 2026-09-14T16:34:06.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147958

*Federal Register* notice: FDA has announced a 12/15 Cardiovascular and Renal Drugs Advisory Committee meeting. Panel members are scheduled to discuss a Novartis supplemental NDA for the angiotensin receptor-neprilysin inhibitor Entresto (sacubitril and valsartan) tablets for the proposed indication of heart failure with preserved ejection fraction. To view the notice, click [here](https://public-inspection.federalregister.gov/2020-23842.pdf?ref=fdaweb.com).